Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets

On November 14, Austin-based Saturn V Capital Management disclosed a buy of Dyne Therapeutics (NASDAQ:DYN), increasing its position by 1.2 million shares and an estimated $20 million based on quarterly average pricing.According to a SEC filing for the period ended September 30, Saturn V Capital Management LP increased its stake in Dyne Therapeutics by about 1.2 million shares compared to the prior quarter. The fund’s position in Dyne Therapeutics is now valued at $33.8 million. The new stake ranks as the fourth-largest in the fund’s portfolio.The buy raised Dyne Therapeutics to 7.4% of Saturn V's 13F reportable AUM.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool